share_log

德琪医药-B(06996.HK):希维奥用于治疗弥漫大B细胞淋巴瘤的适应症成功纳入2024年版国家医保药品目录

Deqi Pharmaceutical-B (06996.HK): The indication for the use of Tislelizumab in the treatment of diffuse large B-cell lymphoma has been successfully included in the 2024 edition of the National Medical Insurance pharmaceutical directory.

Gelonghui Finance ·  Nov 28 17:32

On November 28, Gelonghui reported that德琪医药-B (06996.HK) announced that the new indication for希维奥 (Selinexor tablets) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) who have received at least two lines of systemic treatment has been included in the National Healthcare Security Administration's medication catalog (NRDL) for 2024, which will take effect on January 1, 2025.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment